Lv4
450 积分 2025-09-04 加入
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
2天前
已关闭
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
2天前
已完结
Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
5天前
已完结
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
5天前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
5天前
已完结
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
6天前
已完结
Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer
6天前
已完结
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
6天前
已完结
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
6天前
已完结
Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression
7天前
已完结
皖公网安备34019202002308
